Autoimmune antibodies before immunotherapy

This study looks at what happens to your immune system after you start a type of cancer treatment called a checkpoint inhibitor. The goal is to better understand side effects related to “autoimmunity” (when the immune system starts attacking the body) and improve care.

This study looks for early “predictive clues” (often blood or test markers) that can forecast immune-related side effects in people treated with immune checkpoint medicines. The goal is to help doctors recognize who may be more likely to have these side effects while receiving treatment.

This study measures blood “biomarkers” (signals in blood) to better understand inflammatory diseases, including autoimmune and autoinflammatory conditions. You may be asked to give blood samples now and possibly extra samples if needed for testing.

This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.

This study collects blood, tissue, and other samples from people with autoimmune diseases like Crohn's disease, multiple sclerosis, or lupus. Researchers will study your immune cells (T cells) to learn what they are attacking, which could lead to better treatments in the future.

This study looks at blood “biomarkers,” or measurable body signals, in people with autoimmune diseases, vasculitis, or autoinflammatory conditions. The goal is to better understand these illnesses and how they relate to disease activity.